(Circulation. 1995;91:2520-2527.)
© 1995 American Heart Association, Inc.
Articles |
Alterations of Coagulation and Fibrinolytic and Kallikrein-Kinin Systems in the Acute and Postacute Phases in Patients With Unstable Angina Pectoris
Presented in part at the 1992 annual Scientific Sessions of the American Heart Association, New Orleans, La.
From the Medizinische Klinik (H.M.H., M.J., L.S.), Abt. III and Abt. für Thorax-, Herz- und Gefäßchirurgie (H.P.W., W.H.), Eberhard-Karls-Universität Tübingen, Germany.
Correspondence to Priv-Doz Dr Hans Martin Hoffmeister, Medizinische Universitätsklinik, Abt. III, Otfried-Müller-Straße 10, D-72076 Tübingen, Germany.
Background Unstable angina pectoris is frequently associated with intracoronary thrombus formation. In a prospective study, we investigated in 35 patients with unstable angina pectoris markers of coagulation and the kallikrein-kinin and fibrinolytic systems in the acute and postacute phases.
Methods and Results We determined serially in the patients up to 10 days after admission factor XII and the ß–factor XIIa inhibition, kallikrein-like activity, prekallikrein, C1-esterase inhibitor, kallikrein inhibition, high molecular weight kininogen as indicators of the contact phase and bradykinin generation, thrombin–antithrombin III (TAT) complex as marker of the activated coagulation cascade, fibrinogen, plasminogen, plasminogen activator inhibitor–1 (PAI-1), tissue-type plasminogen activator (TPA), and D-dimers as indicators of the fibrinolytic system. Data were compared with those from control subjects (n=25) and from patients with stable angina pectoris (n=25). In patients with unstable angina pectoris, initially the contact phase and the kallikrein-kinin system were markedly elevated (factor XII, 96±5% versus 117±5%; kallikrein-like activity, 35.7±2.9 versus 27.4±1.3 U/L; high molecular weight kininogen, 52.7±5.2% versus 87.7±3.9%; P<.01 versus control subjects). Contact-phase activation persisted for the following 10 days, whereas the initially enhanced bradykinin generation normalized after 2 days. Furthermore, we had evidence of a hypercoagulative state (TAT, 10.9±3.1 versus 4.5±0.7 µg/L, P<.05; D-dimer, 474±81 versus 272±71 ng/mL) persisting longer than the clinically symptomatic period in association with disturbed fibrinolysis (TPA, 15.9±1.9 versus 5.1±0.4 ng/mL; P<.01; PAI-1, 9.9±2.6 versus 4.6±1.6 AU/mL; P=NS) in the presence of elevated fibrinogen levels.
Conclusions Our data indicate that in patients with unstable angina pectoris, intracoronary thrombus formation is associated with a hypercoagulative state, including activation of the contact phase and of the kallikrein system and increased bradykinin generation. The persistence of this hypercoagulative state, together with a disturbed fibrinolysis, might indicate an increased risk for further coronary events.
Key Words: angina pectoris • kallikrein-kinin system • fibrinolysis • coagulation
This article has been cited by other articles:
 |
|
 |
|
  A. Undas, K. Szuldrzynski, K. E. Brummel-Ziedins, W. Tracz, K. Zmudka, and K. G. Mann Systemic blood coagulation activation in acute coronary syndromes Blood, February 26, 2009; 113(9): 2070 - 2078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ziakas, S. Gavrilidis, E. Souliou, G. Giannoglou, I. Stiliadis, H. Karvounis, G. Efthimiadis, S. Mochlas, M. A. Vayona, A. Hatzitolios, et al. Ceruloplasmin is a Better Predictor of the Long-Term Prognosis Compared With Fibrinogen, CRP, and IL-6 in Patients With Severe Unstable Angina Angiology, February 1, 2009; 60(1): 50 - 59. [Abstract] [PDF]
|
|
|
|
 |
|
 N. N. Lang, I. J. Guthmundsdottir, N. A. Boon, C. A. Ludlam, K. A. Fox, and D. E. Newby Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers smoking, thrombin, and vascular responses in vivo. J. Am. Coll. Cardiol., July 1, 2008; 52(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pleym, V. Videm, A. Wahba, A. Asberg, T. Amundsen, L. Bjella, O. Dale, and R. Stenseth Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively. Eur. J. Cardiothorac. Surg., June 1, 2006; 29(6): 933 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Oliver, D. J. Webb, and D. E. Newby Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2470 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W.J.H. Dielis, M. Smid, H. M.H. Spronk, K. Hamulyak, A. A. Kroon, H. ten Cate, and P. W. de Leeuw The Prothrombotic Paradox of Hypertension: Role of the Renin-Angiotensin and Kallikrein-Kinin Systems Hypertension, December 1, 2005; 46(6): 1236 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bartnik, K. Malmberg, and L. Ryden Management of patients with type 2 diabetes after acute coronary syndromes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 144 - 154. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Sowers, C. Derby, M. L. Jannausch, J. I. Torrens, and R. Pasternak Insulin Resistance, Hemostatic Factors, and Hormone Interactions in Pre- and Perimenopausal Women: SWAN J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4904 - 4910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P J Sheridan and D C Crossman Critical review of unstable angina and non-ST elevation myocardial infarction Postgrad. Med. J., December 1, 2002; 78(926): 717 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. N. Witherow, P. Dawson, C. A. Ludlam, K. A. A. Fox, and D. E. Newby Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy J. Am. Coll. Cardiol., September 4, 2002; 40(5): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ageno and A. G.G. Turpie New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins Can. Med. Assoc. J., April 1, 2002; 166(7): 919 - 924. [Full Text] [PDF]
|
|
|
|
|
|
Y. Hasumura, N. Aoki, K. Kawano, M. Homori, A. Maki, Y. Hioki, K. Ishikawa, and H. Yoshino Platelet-Dependent Thrombin Generation in Patients with Unstable Angina Pectoris Angiology, December 1, 2001; 52(12): 811 - 818. [Abstract] [PDF]
|
|
|
|
|
|
C. Labinjoh, D. E. Newby, M. P. Pellegrini, N. R. Johnston, N. A. Boon, and D. J. Webb Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1402 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. G. Turpie and E. M. Antman Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes Arch Intern Med, June 25, 2001; 161(12): 1484 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Figueras, Y. Monasterio, R. M. Lidon, E. Nieto, and J. Soler-Soler Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2036 - 2043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. ZHANG, K. CLAFFEY, R. SAKTHIVEL, Z. DARZYNKIEWICZ, D. E. SHAW, J. LEAL, Y.-C. WANG, F.-M. LU, and K. R. MCCRAE Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5 FASEB J, December 1, 2000; 14(15): 2589 - 2600. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Ageno and A. G. Turpie Therapy of unstable angina with the low molecular weight heparins Vascular Medicine, November 1, 2000; 5(4): 217 - 223. [Abstract] [PDF]
|
|
|
|
|
|
M. C. Minnema, R. J. G. Peters, R. de Winter, Y. P. T. Lubbers, S. Barzegar, K. A. Bauer, R. D. Rosenberg, C. E. Hack, and H. t. Cate Activation of Clotting Factors XI and IX in Patients With Acute Myocardial Infarction Arterioscler Thromb Vasc Biol, November 1, 2000; 20(11): 2489 - 2493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Goodman, M. Cohen, F. Bigonzi, E. P. Gurfinkel, D. R. Radley, V. Le Iouer, G. J. Fromell, C. Demers, A. G. G. Turpie, R. M. Califf, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the essence study J. Am. Coll. Cardiol., September 1, 2000; 36(3): 693 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Smith, T. H. Fischer, and S. B. Sears Environmental Tobacco Smoke, Cardiovascular Disease, and the Nonlinear Dose-Response Hypothesis Toxicol. Sci., April 1, 2000; 54(2): 462 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Linder, J. Oldgren, N. Egberg, L. Grip, G. Larson, A. Siegbahn, and L. Wallentin The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease Eur. Heart J., April 1, 1999; 20(7): 506 - 518. [Abstract] [PDF]
|
|
|
|
|
|
G. Dangas, J. J. Badimon, D. A. Smith, A. H. Unger, D. Levine, J. H. Shao, P. Meraj, C. Fier, J. T. Fallon, and J. A. Ambrose Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1294 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Hoffmeister, S. Szabo, C. Kastner, M. E. Beyer, U. Helber, S. Kazmaier, H. P. Wendel, W. Heller, and L. Seipel Thrombolytic Therapy in Acute Myocardial Infarction : Comparison of Procoagulant Effects of Streptokinase and Alteplase Regimens With Focus on the Kallikrein System and Plasmin Circulation, December 8, 1998; 98(23): 2527 - 2533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holvoet, J. Vanhaecke, S. Janssens, F. Van de Werf, and D. Collen Oxidized LDL and Malondialdehyde-Modified LDL in Patients With Acute Coronary Syndromes and Stable Coronary Artery Disease Circulation, October 13, 1998; 98(15): 1487 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Geppert, S. Graf, R. Beckmann, S. Hornykewycz, E. Schuster, B. R. Binder, and K. Huber Concentration of Endogenous tPA Antigen in Coronary Artery Disease : Relation to Thrombotic Events, Aspirin Treatment, Hyperlipidemia, and Multivessel Disease Arterioscler Thromb Vasc Biol, October 1, 1998; 18(10): 1634 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Massberg, G. Enders, R. Leiderer, S. Eisenmenger, D. Vestweber, F. Krombach, and K. Messmer Platelet-Endothelial Cell Interactions During Ischemia/Reperfusion: The Role of P-Selectin Blood, July 15, 1998; 92(2): 507 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Klein, A. Buchwald, S. E. Hillis, S. Monrad, G. Sanz, A. G. G. Turpie, J. van der Meer, E. Olaisson, S. Undeland, and K. Ludwig Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease : Fragmin in Unstable Coronary Artery Disease Study (FRIC) Circulation, July 1, 1997; 96(1): 61 - 68. [Abstract] [Full Text]
|
|
|
|
|
|
B. Pitt Risk Stratification in Patients With Unstable Angina : `Deja Vu All Over Again'? Circulation, May 1, 1996; 93(9): 1618 - 1620. [Full Text]
|
|